Home>Topics>Stocks>Roche Holding AG ADR

Roche Holding AG ADR RHHBY

  1. All
  2. Commentary
  3. Headlines
    1. GlaxoSmithKline Needs Healthy Doses Of Good News Post China Scandal

      Headlines

      Mon, 29 Sep 2014

      By Wall Street Playbook : Last week, drug giant GlaxoSmithKline (NYSE: GSK ) was found guilty on bribery charges and has been ordered to pay 3 billion yuan ($489 million) to the Chinese government. U.K.-based Glaxo had been under investigation for almost a year, stemming from allegations that the

    2. Update: Exelixis Announces Very Positive Results From The CoBRIM Trial - Impacts To My Bull Thesis

      Headlines

      Mon, 29 Sep 2014

      results from coBRIM, the Phase III pivotal trial conducted by EXEL's collaborator Genentech, a member of the Roche (OTCQX: RHHBY ) Group. The coBRIM trial was a "randomized, double-blind, placebo-controlled Phase III study evaluating the safety

    3. Exelixis up on clinical trial results

      Headlines

      Mon, 29 Sep 2014

      Roche. Exelixis discovered the drug internally. It entered into a global co-development agreement with Genentech ( OTCQX: RHHBY ) in late 2006. In November 2013, Exelixis exercised its option to co-promote cobimetinib, if approved, in the U.S

    4. Positive Phase 3 results for Roche's melanoma drug

      Headlines

      Mon, 29 Sep 2014

      At the European Society of Medical Oncology (ESMO) Congress today, Roche ( OTCQX: RHHBY ) announced positive from a Phase 3 clinical trial evaluating the safety and efficacy of the combination of cobimetinib plus Zelboraf

    5. Premature Combination Use Of Belviq And Phentermine Is A Risk

      Headlines

      Sun, 28 Sep 2014

      increase in ma jor adverse cardiovascular events [MACE] in the SCOUT trial. The market for Orlistat, from Roche (OTCQX: RHHBY ) and Glaxo Smith Kline (NYSE: GSK ), remains limited because of gastrointestinal adverse effects. The diabetes drug, Avandia

    6. Roche cancer drugs show positive results in two label expansion clinical trials

      Headlines

      Thu, 25 Sep 2014

      Roche's ( OTCQX: RHHBY ) Avastin (bevacizumab) and Xeloda (capecitabine) achieve their primary endpoints in two Phase 3 clinical trials in HER2-negative

    7. CareDx settles royalty dispute with Roche

      Headlines

      Wed, 17 Sep 2014

      CareDx ( CDNA -4.6% ) settles its arbitration case with Roche ( OTCQX: RHHBY -0.3% ) over unpaid PCR-related royalties on AlloMap revenue. CareDx agrees to pay Roche $2,827,220 to settle past

    8. The Ultimate Stock-Pickers’ Top 10 Dividend Stocks

      Headlines

      Tue, 16 Sep 2014

      Sanofi* SNY 4 Wide 56.43 0.88 3.3 Medium 5 3 Roche* RHHBY 3 Wide 36.7 1.05 3 Low 5 - Eli Lilly LLY 3 Wide 65.27 ..... for Pfizer PFE, General Electric GE, Sanofi SNY, and Roche RHHBY , but the yields remain fairly comparable, even though the

    9. Roche initiates GA drug Phase 3 trial

      Headlines

      Mon, 15 Sep 2014

      Roche ( OTCQX: RHHBY ) commences a Phase 3 clinical trial to evaluate the safety and efficacy of lampalizumab for the treatment of patients with geographic

    10. Incyte Pharmaceutical: Top Idea For 2H14 With 2 Free Call Options Driving M&A Valuation To $93, Gilead Most Likely Suitor

      Headlines

      Thu, 11 Sep 2014

      By Dr. Paul Nunzio DeSantis, Pharm.D : Abbvie's (NYSE: ABBV )'s proactive and strategic efforts throughout 2014 are undoubtedly welcome measures by shareholders who are increasingly weary of ABBV's dependence on Humira as patent expiration arrives in 2016. We specifically support their £53.80 bid

    « Prev12345Next »
    Content Partners